

Hypoxia Inducible Factor-2 α Predominantly Contributes to Cortical Phenotype in *Vhl* cKO Mice

Sarah V. Mendoza¹, Benjamin Osipov¹, Deepa K. Muruges², Blaine A. Christiansen¹, Gabriela G. Loots^{1,2}, Damian C. Genetos¹, Clare E. Yellowley¹

¹ University of California, Davis, CA, ² Lawrence Livermore National Laboratories, Livermore, CA

svmendoza@ucdavis.edu

Disclosures: Sarah V. Mendoza (N), Benjamin Osipov (N), Deepa K. Muruges (N), Blaine A. Christiansen (N), Gabriela G. Loots (N), Damian C. Genetos (N), Clare E. Yellowley (N)

INTRODUCTION: Hypoxia inducible factors (HIFs) are heterodimeric transcription factors that respond to changes in cellular oxygen levels. HIFs are composed of an oxygen-dependent α subunit (HIF α) and a constitutively expressed β subunit (HIF β). Under normoxic conditions, HIF α is hydroxylated via prolyl hydroxylase domain protein (PHD) and targeted for 26S proteasomal degradation via an E3 ligase complex Von-Hippel Lindau (VHL). Under hypoxic conditions, hydroxylation via PHD is inhibited, allowing for HIF- α stabilization and accumulation in the cytosol. Stabilized HIF α complexes with HIF β in the nucleus then binds HIF-response elements in target genes promoting angiogenesis, osteogenic differentiation and proliferation, glucose uptake, and anaerobic glycolysis (1). Thus, VHL serves as a master regulator of HIF α activity by targeting its degradation. Our studies have shown that deletion of *Vhl* in osteocytes but not osteoblasts (*Dmp1-cre; Vhl*^{fl/fl}) produces a robust skeletal phenotype, characterized by dramatic increases in both cortical and trabecular microarchitecture compared to age-matched wild-type mice (2). Our previous work deleting *Hif1a* or *Hif2a* in osteocytes showed no effect on skeletal microarchitecture, however, expressing a degradation resistant osteocytic HIF-2 α , not HIF-1 α , generated a high bone mass phenotype (3). Therefore, we hypothesize that osteocytes may only require HIF-2 α to transduce *Vhl* signaling. The objective of this study was to evaluate whether HIF-2 α is the predominant isoform required to transduce *Vhl* signaling in osteocytes, culminating in a high bone mass phenotype.

METHODS: *Hif1a*^{fl/fl} (#007561), *Hif2a*^{fl/fl} (#008407) and *Vhl*^{fl/fl} (#004081) mice were purchased from Jackson Laboratories. To generate double knock-out mice, *Hif1a*^{fl/fl} and *Hif2a*^{fl/fl} mice were bred with *Vhl*^{fl/fl} mice for several generations to produce homozygous, dual-floxed *Vhl*^{fl/fl}/*Hif1a*^{fl/fl} and *Vhl*^{fl/fl}/*Hif2a*^{fl/fl} mice, which were bred with mice expressing *cre*-recombinase driven by the 10 kb-*Dmp1* promoter (*Dmp1-cre; Vhl*^{fl/fl}, *Hif1a*^{fl/fl} and *Dmp1-cre; Vhl*^{fl/fl}, *Hif1a*^{fl/fl} mice with osteocyte conditional deletion of *Vhl* and *Hif1a* (*Vhl; Hif1a* cKO) or *Vhl* and *Hif2a* (*Vhl; Hif2a* cKO). Twelve female mice were euthanized at 16 weeks of age (n = 3/group); the left femur was dissected, fixed, and scanned per (2) to evaluate femoral mid-diaphyseal cortical bone tissue mineral density distribution. Tissue mineral density distributions (TMDD) were obtained by distributing voxels into 100 evenly spaced bins (4–1,500 mg HA/cm³). Mean calcium content (Ca_{MEAN}), peak calcium content (Ca_{PEAK}), and width at half-maximum (Ca_{WIDTH}) were calculated as per (4). Three-point bending mechanical testing (ElectroForce 3200; TA Instruments) was conducted on unfixed contralateral femora (3 mice per genotype) to evaluate structural and tissue mechanical properties. Data were analyzed using multiple comparison ordinary one-way ANOVA tests, where p<0.05 was statistically significant.

RESULTS: Our analysis of tissue-level calcium distribution revealed reductions in multiple cortical bone parameters in single *Vhl* or dual mutant *Vhl; Hif1a* cKO mice that was not observed in *Vhl; Hif2a* cKO mice. Hydroxyapatite-calibrated heatmap of TMDD (**Fig. 1A**) and TMDD profiles (**Fig. 1B**) of mid-diaphyseal cortical bone revealed marked heterogeneity as a function of *Vhl* and *Hif1a* deletion. Loss of *Vhl* with either *Hif1a* (*Vhl; Hif1a* cKO) or *Hif2a* (*Vhl; Hif2a* cKO) reduced TMDD heterogeneity to *cre*-negative levels (**Fig. 1C**). Both single (*Vhl* cKO) and double mutants (*Vhl; Hif1a* cKO and *Vhl; Hif2a* cKO) demonstrated reduced peak calcium compared to *cre*-negative controls (**Fig. 1D**). Loss of *Vhl* and *Hif1a* dramatically reduced mean mineralization compared to *cre*-negative controls (**Fig. 1E**). Elastic modulus of the *Vhl; Hif1a* cKO was reduced to *Vhl* cKO levels, whereas the *Vhl; Hif2a* cKO was indistinguishable from *cre*-negative controls (**Fig. 1F**).

DISCUSSION: The unique impacts of HIF α isoforms on skeletal health remain understudied. We have previously used an osteocytic model of stabilized HIF α - signaling (*Vhl* cKO) to investigate effects on bone development and strength, yet the relative contribution of unique HIF- α isoforms was not addressed. By generating mice with compound deletion of *Vhl* and *Hif1a* or *Hif2a*, we found that deletion of *Vhl; Hif1a* dramatically reduced cortical mean density and moderately reduced elastic modulus, indicating impaired cortical tissue and mineral bone quality. Dual deletion of *Hif2a* and *Vhl* generated mild reductions in cortical mean density and elastic modulus and reduced cortical peak mineral to *Vhl* cKO levels. Our studies suggest that osteocytic HIF-2 α appears to predominantly determine cortical mineralization distribution in the *Vhl* cKO mouse.

SIGNIFICANCE/CLINICAL RELEVANCE: Osteoporotic fractures caused by weak and brittle bones are associated with significant decreases in mobility, quality of life, and in some cases, significant financial burden due to rehabilitative and/or long-term disability care. Osteocytic *Vhl* deletion drives a high bone mass phenotype, thus, identifying the mechanisms by which this increase in bone mass is generated can be used to identify novel therapeutic targets to subvert poor bone quality.

REFERENCES: (1) Semenza GL. *J Bone Miner Res.* 2014;29(4):820-829. (2). Loots GG et al. *Vhl* deficiency in osteocytes produces high bone mass and hematopoietic defects. *Bone.* 2018 Nov 116:307-314. (3) Mendoza SV et al. *JBMR Plus.* 2023 Feb 17;7(4). (4) Borah B et al. *Bone.* 2006 Aug;39(2):345-52.

ACKNOWLEDGEMENTS: This work was supported by NIH 5-R01 AR073772-02 (CEY, DCG) and T32 GM007377 (SVM). Deepa K. Muruges and Gabriela G. Loots performed work under the auspices of the USDOE by LLNL (DE-AC52-07NA27344).

